Credit: Shutterstock photoAvalanche Biotechnologies, an early-stage biotech developing gene therapies for wet AMD and other ophthalmic diseases, filed on Monday with the SEC to raise up to $86 million in an initial public offering. The Menlo Park, CA-based company, which was founded in 2006, plans to list on the NASDAQ under the symbol AAVL. Avalanche Biotechnologies initially filed confidentially on May 30, 2014. Jefferies, Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
